The discovery of potent SIRT6 inhibitors like compound 11e, with its remarkable selectivity and anti-metastatic properties, highlights the therapeutic potential of targeting SIRT6 in pancreatic cancer. This evidence concerns the gene SIRT6 and pancreatic neoplasm.